Antitumor activity of an EpCAM/CD3-bispecific BiTE antibody during long-term treatment of mice in the absence of T-cell anergy and sustained cytokine release.

@article{Amann2009AntitumorAO,
  title={Antitumor activity of an EpCAM/CD3-bispecific BiTE antibody during long-term treatment of mice in the absence of T-cell anergy and sustained cytokine release.},
  author={Maria Amann and Sandrine d'Argouges and Grit Lorenczewski and Klaus Brischwein and Roman Kischel and Ralf Lutterbuese and Susanne Mangold and Doris Rau and J{\"o}rg Volkland and Stefan Pflanz and Tobias Raum and Markus Muenz and Peter Kufer and Bernd Schlereth and Patrick A. Baeuerle and Matthias Friedrich},
  journal={Journal of immunotherapy},
  year={2009},
  volume={32 5},
  pages={452-64}
}
muS110 is a BiTE antibody bispecific for murine EpCAM (CD326) and murine CD3. MT110, its human-specific analog, is in a clinical phase 1 trial for treatment of patients with adenocarcinoma of the lung or gastrointestinal tract. Recent studies have shown a therapeutic window for muS110, have explored single-dose toxicity of muS110, and have found that a 1-week low-dose treatment dramatically increased the tolerability of mice to very high doses of muS110 (Cancer Immunol. Immunother. 2009;58:95… CONTINUE READING
Related Discussions
This paper has been referenced on Twitter 1 time. VIEW TWEETS

Citations

Publications citing this paper.
Showing 1-10 of 25 extracted citations

Transient lymphocyte decrease due to adhesion and migration following catumaxomab (anti-EpCAM x anti-CD3) treatment in vivo.

Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico • 2012
View 9 Excerpts
Highly Influenced

Recent advances of bispecific antibodies in solid tumors

Journal of hematology & oncology • 2017
View 1 Excerpt

Protein Targeting Compounds

Advances in Experimental Medicine and Biology • 2016
View 1 Excerpt

Similar Papers

Loading similar papers…